On 17th December 2012, Chugai Pharmaceutical and Debiopharm entered into a licensing agreement regarding Debio 1347 (FF284), an agent discovered by Chugai that is about to begin clinical development in oncology.
Under the agreement, Chugai will grant Debiopharm an exclusive licence to develop and commercialise FF284 in all countries worldwide, including Japan. Under the same agreement, Chugai will grant a non-exclusive licence to develop and commercialise a companion diagnostic for FF284. According to the terms of the licence, Debiopharm and Chugai will collaborate to conduct a Phase I dose-escalation study. In return for the licence, Chugai will receive an undisclosed up-front fee, and milestone and royalty payments from Debiopharm.
|Agreement Status:||New||Date Announced:||8 Jan 2013|
|Date Last Reported:||Duration:|
|Est Total Value:||Investment To Date:|
|Generic / Brand Name:||Debio 1347|
|Therapeutic Area:||Antineoplastic and Immunomodulating Agents|
|Techonology/Field:||Diagnostics Drug development|